Home | Welcome to Contract Pharma   
Last Updated Tuesday, March 3 2015

Print

Topics - Inspections


Refine by Date:
From: To:
Published February 17, 2015
Sterile fill production facility found in accordance with regulatory requirements Read More »
Published February 9, 2015
Found to be compliant with cGMP principles and guidelines Read More »
Published February 2, 2015
Allows for expanded manufacturing and packaging services for U.S. market Read More »
Published January 28, 2015
To manufacture Amotosalen API for Cerus Read More »
Published January 20, 2015
Will produce immunotherapy for the treatment of melanoma Read More »
Published January 13, 2015
Bedford facility to manufacture commercial drug for U.S. distribution Read More »
Published January 12, 2015
New VAI classification permits FDA approval of new products Read More »
Published December 17, 2014
Site compliant with GMP but Form 483 notes three inspectional observations Read More »
Published September 4, 2014
Complies with the quality GMP & GDP standards Read More »
Published September 3, 2014
Will test commercial drug product for the European market Read More »
Published August 18, 2014
To manufacture API for branded commercial drug Read More »
Published August 5, 2014
Ireland facility gains pre-approval Read More »
Published July 22, 2014
Will produce NME for U.S. market Read More »
Published July 8, 2014
Gains certification by Belgium and EU authorities Read More »
Published July 8, 2014
Inspection covered quality system and lab facilities in Torrance, CA Read More »


Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On